22 April 2024: Articles
Recurrent Marginal Zone Lymphoma with Bone Marrow Involvement Detected by F-FDG PET/CT and Biopsy: A Diagnostic Challenge
Mistake in diagnosis
Yeong-Shin Hsiao1EF, Shu-Chane Shen2BCD, Shih-Chuan Hsiao3BCDEF*DOI: 10.12659/AJCR.943275
Am J Case Rep 2024; 25:e943275
Abstract
BACKGROUND: Marginal zone lymphoma is a low-grade, B-cell, non-Hodgkin lymphoma. Bone marrow involvement (BMI) of leukemia or lymphoma can usually be displayed in fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT) with high standardized uptake values (SUV), while diffuse homogeneous ¹⁸F-FDG bone marrow uptake (BMU) in PET/CT primarily reflects hyperplastic bone marrow status. This report is of a 64-year-old man presenting with anemia and a diagnosis of recurrent marginal zone lymphoma with bone marrow involvement identified with 18F-FDG PET/CT imaging and biopsy.
CASE REPORT: A 64-year-old man with severe anemia and body weight loss of 7 kg in 1 month was diagnosed with marginal zone lymphoma, stage III, in July 2011. He went into complete remission in April 2012 after 6 cycles of chemotherapy, with Hb restored. Anemia and diffuse homogeneous ¹⁸F-FDG BMU in PET/CT were then noted during a routine check-up in October 2021, and recurrent disease was established through positive biopsy of subcutaneous nodules and bone marrow. Subsequent complete remission after 6 cycles of combination therapy was validated with pathologically negative BMI, the resolution of the slightly enhanced ¹⁸F-FDG BMU in PET/CT, and restored hemoglobin.
CONCLUSIONS: This report has highlighted the importance of follow-up for patients with lymphoma and supports the diagnostic role of ¹⁸F-FDG PET/CT imaging and the pathological verification in identifying malignant involvement in bone marrow.
Keywords: Lymphoma, B-Cell, Marginal Zone, Bone Marrow, Positron Emission Tomography Computed Tomography, case reports
Introduction
Marginal zone lymphoma makes up 7% of all lymphomas and is a B-cell non-Hodgkin lymphoma that first infiltrates the outer zone of follicles and slowly spreads centrally into the perifollicular mantle zone and germinal center [1,2]. While clinical presentation, blood tests, and radiological findings are all essential to the diagnostic process, marginal zone lymphoma, as with any other type of lymphoma, can be confirmed histopathologically through the biopsy of suspected tissues [1]. It is classified into 4 stages according to the Ann Arbor staging system [2]. Possible treatment includes watch and wait, radiotherapy, immunochemotherapy, and target therapy, as well as the antibiotic eradication of
Fluorine-18-fluorodeoxyglucose (18F-FDG) uptake in positron emission tomography/computed tomography (PET/CT) reflects the level of cellular metabolism of glucose in the tissues and is therefore a useful tool for diagnosing and monitoring malignant diseases, as cancer cells generally have a higher glucose consumption than normal cells [5]. The brighter the signal, the higher the glucose intake [5]. Malignant infiltration in bone marrow is often demonstrated as simultaneous focal or asymmetric hot spots in PET/CT with a high maximum standardized uptake value (SUVmax) of 18F-FDG [6,7].
Challenges in diagnosing lymphoma through 18F-FDG uptake in PET/CT have also been documented in other case reports: one reports a patient with Hodgkin disease and diffuse low 18F-FDG bone marrow uptake (BMU) without definite bone marrow infiltration [8], while the other describes marginal zone lymphoma with focal 18F-FDG uptake in lymph nodes [9].
This report is of a 74-year-old man presenting with anemia and a diagnosis of recurrent marginal zone lymphoma with bone marrow involvement identified with 18F-FDG PET/CT imaging and biopsy.
Case Report
In July 2011, a 64-year-old man with anemia (hemoglobin [Hb]: 37 g/L) and body weight loss of 7 kg in 1 month was diagnosed with marginal zone lymphoma, stage III, through lymph node biopsy. With no response to initial treatment via HP eradication, he received 6 cycles of cyclophosphamide, oncovin, and prednisolone (COP) in 5 months. He went into complete remission in April 2012, and Hb was restored to 120 g/L. For the next decade, he received regular follow-ups and was not administered drugs for chronic disease or hematopoietic cytokines (such as granulocyte colony-stimulating factor or erythropoietin). Hb levels remained within normal range, and he also remained completely asymptomatic.
During a routine check-up in October 2021, anemia (Hb: 65 g/L, white blood cell count: 4.53×109/L, platelet count: 293×109/L) was noted. Recurrent disease was then pathologically established through excisional biopsy of one of multiple abdominal subcutaneous nodules, with histopathological features corresponding to those of the marginal zone lymphoma from July 2011. 18F-FDG PET/CT (Figure 1A) and maximum intensity projection (MIP) (Figure 1B) images displayed diffuse, homogeneously distributed low 18F-FDG BMU, while bone marrow involvement (BMI) was subsequently confirmed by bone marrow biopsy, which revealed hypercellularity with diffuse infiltration of lymphoma cells (Figures 2, 3).
The patient received 6 cycles of combination therapy with reduced dosage of bendamustine, lenalidomide, and rituximab for the next 7 months [10]. Complete remission was achieved in June 2022, as depicted by subtle 18F-FDG BMU in PET/CT (Figure 4A) and MIP (Figure 4B), as well as negative histo-pathological results from bone marrow re-biopsy, which revealed normocellular hematopoietic cells without pathological evidence of lymphoma cell involvement (Figures 5, 6). Furthermore, normal hemogram, as well as an improvement in performance status from Eastern Cooperative Oncology Group (ECOG) 3 to ECOG 1, has been recorded since February 2022.
Discussion
Ambiguous lesions with low 18F-FDG SUV in PET/CT are generally categorized as benign processes. As opposed to higher BMU with a focal or asymmetric pattern, which is almost always associated with myeloproliferative disorders and malignant diseases, leading causes of diffuse homogeneous low 18F-FDG BMU in PET/CT most commonly reflect hyperplastic bone marrow status and include long-standing anemia, administration of hematopoietic cytokines, and inflammation [7,8,11,12]. Large-scale clinical analyses suggest that malignancy is usually first considered when SUVmax is above 6.560 [6], while SUVmax >10 implies a higher likelihood for aggressive non-Hodgkin lymphoma [13].
This case report serves as a warning that we must be alert to potential malignant BMI even with the concurrence of diffuse homogeneous low 18F-FDG BMU in PET/CT images and enhanced bone marrow hematopoietic conditions, such as insufficient peripheral circulating blood cells or the administration of hematopoietic cytokines. Although peculiar lesions may be distinguished as malignant or benign based on their standardized uptake value (SUV) in PET/CT, pathological evaluation cannot always be categorically omitted.
In other words, based on the statistics, the possibility of malignant BMI in diffuse homogeneous low 18F-FDG BMU in PET/ CT is not always taken into account at first [14–16]. However, we reported pathologically established bone marrow malignancy in what was expected to be a benign case, with recurrent diffuse BMI of lymphoma cells. The resolution of diffuse homogeneous 18F-FDG BMU in PET/CT and negative pathological results in bone marrow after treatment illustrate malignancy-free status, with a normal hemogram that reflects recovery of hematopoiesis from suppressed status due to malignant BMI.
We compared our case with 2 similar previous case reports. The first is a 2003 case report of a patient with Hodgkin disease who also had diffuse low 18F-FDG BMU that was otherwise only seen in conditions with increased marrow hematopoiesis [8]. Unlike in our patient, however, the diagnosis was not pathologically proven through bone marrow biopsy [8], which meant that bone marrow involvement could not be confirmed. The second case report, in 2023 described a patient, diagnosed with marginal zone lymphoma through the biopsy of a subcutaneous nodule, whose PET/CT images showed localized enhanced signal of 18F-FDG in lymph nodes [9]. The focally increased up-take could be interpreted as a possible characteristic of malignancy, although definite pathological disease staging was not possible [9]. In contrast, the PET/CT images in our case displayed an evenly distributed, mild 18F-FDG uptake in bone marrow throughout the whole body, a feature commonly and arbitrarily only associated with benign diseases. Our case is unique in that the patient’s diagnosis, which was fully expected to be benign based on the radiological findings, was in the end pathologically proven to be malignant. In our presented case, the correlation between the patient’s diffuse homogeneous low 18F-FDG bone marrow uptake in PET/CT and positive bone marrow involvement was not only confirmed before treatment, but also validated again after treatment through the resolution of diffuse BMU and negative bone marrow biopsy. The confirmed malignant diagnosis and resulting effective treatment emphasizes our message that the surveillance of pathological bone marrow status is always warranted even if signs and symptoms imply otherwise.
Conclusions
This report has highlighted the importance of follow-up for patients with low-grade lymphoma, including marginal zone lymphoma, and supports the diagnostic role of 18F-FDG PET/ CT imaging and the pathological verification in identifying malignant involvement in bone marrow.
Figures
Figure 1.. Imaging of initial recurrence on October 22, 2021. (A) Fluorine-18-fluorodeoxyglucose positron emission tomography/ computed tomography (18F-FDG PET/CT) scan shows diffuse homogenous low bone marrow uptake (BMU) (maximum standardized uptake value (SUVmax) 3.63 in the spine and 3.22 in the pelvis, with normal liver SUVmax 2.87). (B) Maximum intensity projection (MIP) image shows homogeneously distributed enhanced BMU. Figure 2.. Histopathological findings of initial recurrence on October 27, 2021. (A, B) Hematoxylin and eosin (H&E) staining of bone marrow shows hypercellularity with magnified diffuse infiltration of small to medium-sized lymphoma cells. Objective magnification A ×40 and B ×400. Figure 3.. Histopathological findings of initial recurrence on October 27, 2021. (A, B) Immunohistochemical (IHC) staining of bone marrow reveals CD3(-) and CD20(+). Figure 4.. Imaging after treatment, on June 7, 2022. (A) Fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) scan shows subtle 18F-FDG uptake (maximum standardized uptake value (SUVmax) 2.69 in the spine and 1.02 in the pelvis). (B) Maximum-intensity projection (MIP) image shows no obvious bone marrow uptake (BMU) compared to Figure 1. Figure 5.. Histopathological findings after treatment on June 27, 2022. (A, B) Hematoxylin and eosin (H&E) staining of bone marrow shows normocellularity with normal hematopoietic cells without evidence of lymphoma involvement. Objective magnification A ×40 and B ×400. Figure 6.. Histopathological findings after treatment, on June 27, 2022. (A, B) Immunohistochemical (IHC) staining of bone marrow reveals CD3(-) and CD20(-).References:
1.. Herold GI, Hämatologie: Innere Medizin 2020, 2020; 78-84, Köln, De Gruyter [in German]
2.. Jamil A, Mukkamalla SKR, Lymphoma. [Updated 2023 Jul 17]: StatPearls [Internet], 2024, Treasure Island (FL), StatPearls Publishing Available from: https://www.ncbi.nlm.nih.gov/books/NBK560826/
3.. Buske C, „Marginalzonenlymphom“ – Therapie: Kompetenznetz Maligne Lymphome e.V Available from: [in German]https://lymphome.de/lymphome/marginal-zonenlymphom/therapie/
4.. Farooq U, Chakinala RC, MALToma [Updated 2023 Apr 16]: StatPearls [Internet], 2024, Treasure Island (FL), StatPearls Publishing Available from: https://www.ncbi.nlm.nih.gov/books/NBK553122/
5.. Ashraf MA, Goyal A, Fludeoxyglucose (18F) [Updated 2023 Aug 28]: StatPearls [Internet], 2024, Treasure Island (FL), StatPearls Publishing Available from: https://www.ncbi.nlm.nih.gov/books/NBK557653/
6.. Alam MS, Fu L, Ren YY: Medicine (Baltimore), 2016; 95; e5579
7.. Schöder H, Noy A, Gönen M: J Clin Oncol, 2005; 23; 4643-51
8.. Chiang SB, Rebenstock A, Guan L, Diffuse bone marrow involvement of Hodgkin lymphoma mimics hematopoietic cytokine-mediated FDG up-take on FDG PET imaging: Clin Nucl Med, 2003; 28; 674-76
9.. Romo WCM, Aponte Barrios WO, Bayona JAC, Extranodal marginal zone lymphoma: A case report: Radiol Case Rep, 2023; 19(1); 12-16
10.. Nowakowski GS, LaPlant B, Macon WR, Bendamustine and rituximab and lenalidomide (BRR) in the treatment of relapsed and refractory low grade non-Hodgkin lymphoma (NHL): Final results of phase 1 study NCCTG N1088/ALLIANCE: J Clin Oncol, 2015; 33; S8540
11.. MacManus MP, Seymour JF, Hicks RJ, Overview of early response assessment in lymphoma with FDG-PET: Cancer Imaging, 2007; 7; 10-18
12.. Inukai J, Ohnishi A, Tagawa S, Diseases showing diffuse bone uptake on FDG-PET: J Nucl Med, 2019; 60; S1155
13.. Kaddu-Mulindwa D, Altmann B, Held G, FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL >60 trials: Eur J Nucl Med Mol Imaging, 2021; 48; 3550-59
14.. Nakajima R, Moskowitz AJ, Michaud L, Baseline FDG-PET/CT detects bone marrow involvement in follicular lymphoma and provides relevant prognostic information: Blood Adv, 2020; 4; 1812-23
15.. Özpolat HT, Yilmaz E, Goksoy HS, Detection of bone marrow involvement with FDG PET/CT in patients with newly diagnosed lymphoma: Blood Res, 2018; 53; 281-87
16.. Chiang SB, Rebenstock A, Guan L, Diffuse bone marrow involvement of hodgkin lymphoma mimics hematopoietic cytokine-mediated FDG up-take on FDG PET imaging: Clin Nucl Med, 2003; 28; 674-76
Figures
In Press
Case report
Late-Onset Hemophagocytic Lymphohistiocytosis in a Lung Transplant Patient: A Case of T-Cell Post-Transplan...Am J Case Rep In Press; DOI: 10.12659/AJCR.944761
Case report
Dantrolene for Control of Refractory Shivering in Severe Traumatic Brain Injury: A Case StudyAm J Case Rep In Press; DOI: 10.12659/AJCR.944980
Case report
Precision Extraction of Lingual Mandibular Supernumerary Teeth Using Dynamic Navigation and High-Speed Hand...Am J Case Rep In Press; DOI: 10.12659/AJCR.945262
Case report
Anesthetic Strategies and Challenges in the Separation of Pygopagus Conjoined Twins: A Case ReportAm J Case Rep In Press; DOI: 10.12659/AJCR.944776
Most Viewed Current Articles
21 Jun 2024 : Case report 59,306
Intracranial Parasitic Fetus in a Living Infant: A Case Study with Surgical Intervention and Prognosis Anal...DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report 42,927
Neurocysticercosis Presenting as Migraine in the United StatesDOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
10 Jan 2022 : Case report 32,489
A Report on the First 7 Sequential Patients Treated Within the C-Reactive Protein Apheresis in COVID (CACOV...DOI :10.12659/AJCR.935263
Am J Case Rep 2022; 23:e935263
23 Feb 2022 : Case report 20,116
Penile Necrosis Associated with Local Intravenous Injection of CocaineDOI :10.12659/AJCR.935250
Am J Case Rep 2022; 23:e935250